

1. Please replace claim 1 with amended claim 1:

1. A chimeric peptide comprising a μ opioid receptor binding moiety at its N-terminus and an agonist Substance P receptor binding moiety at its C-terminus, wherein said peptide induces analgesia.

2. Please replace claim 28 with amended claim 28:

28. The peptide of claim 1, wherein said opioid receptor binding moiety is a μ receptor agonist.

3. Please replace claims 31-33 with amended claims 31-33:

31. The peptide of claim 30 wherein said opioid receptor binding moiety is a peptide having any one of SEQ ID Nos: 1-11, or an N-terminal fragment or N-terminal derivative thereof.
32. The peptide of claim 30 wherein said opioid receptor binding moiety is endomorphin 1, endomorphin 2, an N-terminal fragment, or an N-terminal derivative thereof.
33. The peptide of claim 32 wherein said opioid receptor binding moiety is a peptide having SEQ ID No: 2 or 3, or an N-terminal fragment or N-terminal derivative thereof.

4. Please replace claims 45 and 46 with amended claims 45 and 46:

45. The peptide of claim 1, wherein said agonist Substance P receptor binding moiety comprises Substance P, a C-terminal Substance P fragment, or a C-terminal Substance P derivative.
46. The peptide of claim 1, wherein the $-\text{COOH}$ moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is protected.

5. Please replace claim 49 with amended claim 49:

49. The peptide of claim 48 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 21, 36 and 38-41, or a C-terminal fragment or C-terminal derivative thereof.

6. Please replace claim 53 with amended claim 53:

53. The peptide of claim 52 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 25-27, or a C-terminal fragment or C-terminal derivative thereof.

7. Please replace claims 56 and 57 with amended claims 56 and 57:

56. The peptide of claim 55 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 28-30, or a C-terminal fragment or C-terminal derivative thereof.
57. The peptide of claim 1 wherein the opioid receptor binding moiety is endomorphin 1, endomorphin 2, or an N-terminal fragment or N-terminal derivative thereof; and the Substance P receptor binding moiety is Substance P, or a C-terminal fragment or C-terminal derivative thereof.

8. Please replace claim 61 with amended claim 61:

61. The peptide of claim 1 wherein said peptide comprises at least one D-amino acid.

9. Please replace claim 64 with amended claim 64:

64. The pharmaceutical composition of claim 62, wherein said peptide induces analgesia when administered to a mammal.

10. Please replace claims 69-74 with amended claims 68-74:

- 69. The pharmaceutical composition of claim 62, wherein said opioid receptor binding moiety is a μ receptor agonist.
- 70. The pharmaceutical composition of claim 69 wherein the N-terminal amino acid residue of said opioid receptor binding moiety is a free amine.
- 71. The pharmaceutical composition of claim 70 wherein the N-terminal amino acid residue of said opioid receptor binding moiety is Tyr.
- 72. The pharmaceutical composition of claim 71 wherein said opioid receptor binding moiety is a peptide having any one of SEQ ID Nos: 1-11, or an N-terminal fragment or N-terminal derivative thereof.
- 73. The pharmaceutical composition of claim 71 wherein said opioid receptor binding moiety is endomorphin 1, endomorphin 2, an N-terminal fragment, or an N-terminal derivative thereof.
- 74. The pharmaceutical composition of claim 73 wherein said opioid receptor binding moiety is a peptide having SEQ ID No: 2 or 3, or an N-terminal fragment or N-terminal derivative thereof.

11. Please replace claims 86-100 with amended claims 86-100:

- 86. The pharmaceutical composition of claim 62, wherein said agonist Substance P receptor binding moiety comprises Substance P, a C-terminal Substance P fragment, or a C-terminal Substance P derivative.

87. The pharmaceutical composition of claim 62, wherein the -COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is protected.
88. The pharmaceutical composition of claim 87 wherein the -COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is amidated.
89. The pharmaceutical composition of claim 88 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is Met-NH₂.
90. The pharmaceutical composition of claim 89 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 21, 36 and 38-41, or a C-terminal fragment or C-terminal derivative thereof.
91. The pharmaceutical composition of claim 87 wherein the -COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is esterified.
92. The pharmaceutical composition of claim 91 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is a methyl ester.
93. The pharmaceutical composition of claim 92 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is Gly-OMe, Lys-COOMe or Arg-COOMe.
94. The pharmaceutical composition of claim 93 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 25-27, or a C-terminal fragment or C-terminal derivative thereof.
95. The pharmaceutical composition of claim 91 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is an ethyl ester.